Alpine Immune Sciences, Inc.

Single-Patient EA Policies/Criteria Alpine will evaluate an expanded access request based on a variety of factors, which include but are not limited to: • The request for expanded access is submitted by a treating physician, who is appropriately licensed; • The patient’s condition is serious or life-threatening and there is a reasonable potential that the investigational drug has the potential to provide a benefit to the patient with an acceptable level of risk; • Participation in a clinical trial is not an option, either because the patient is not eligible to enroll or because there are no appropriate ongoing clinical trials; • The proposed dose of the investigational drug is within the existing dose range for which human safety data are available; • The investigational product is available for treatment use without compromising supplies that have been designated for other uses. Requests will be considered on a case-by-case basis. If a request for expanded access is granted, the requesting physician must agree to obtain appropriate regulatory and ethics committee approvals and comply with regulatory obligations, including obtaining patient consent, patient monitoring, and safety reporting. Available Therapies via Single-Patient EA ALPN-101